Working… Menu

A Trial of MBC-11 in Patients With CIBD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02673060
Recruitment Status : Completed
First Posted : February 3, 2016
Last Update Posted : March 29, 2016
Information provided by (Responsible Party):
Osteros Biomedica Ltd

Brief Summary:
This study evaluates MBC-11 (a conjugate of a bone-targeting vehicle (etidronate) and a cytostatic agent [ara-C] in patients with malignant tumors with CIBD. This is a first use in human.

Condition or disease Intervention/treatment Phase
Bone Metastasis Drug: MBC-11 Phase 1

Detailed Description:

A standard "3+3" dose escalation design to determine Maximum Tolerated Dose with consecutive different dose level cohort recruitment.

The following dose levels to be investigated: 0.5 mg/kg, 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kgm 20 mg/kg. The study for each patient consists of 14-days screening period, single dose administration of MBC-11 followed by 7-day safety monitoring and then 2 cycles of multiple use of MBC-11 (28 days each cycle, study drug is administered at Days1-5). In case of partial metabolic reaction/stable metabolic reaction therapy maybe prolonged up to 4 cycles (at investigator and sponsor consideration)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)
Study Start Date : July 2014
Actual Primary Completion Date : November 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: dose escalation of MBC-11
MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
Drug: MBC-11
0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: up to 20 weeks ]
    evaluation of adverse events, physical examination, laboratory parameters

  2. Dose Limiting Toxicity [DLT] [ Time Frame: up to 20 weeks ]
    dose limiting toxicity is graded according to NCI CN CFT version 4

  3. Maximum tolerated dose [ Time Frame: up to 20 weeks ]

Secondary Outcome Measures :
  1. Maximum Plasma Concentration [Cmax] of MBC-11 [ Time Frame: 5 weeks ]
    Cmax will be evaluated during Cycle 1

  2. Pharmacodynamic parameters [ Time Frame: up to 20 weeks ]
    Levels of bone turnover markers is measured

  3. Fluorodeoxyglucose positron emission tomography-computed tomography [FDG PET-CT] response after cycle 2 and cycle 4 therapy [ Time Frame: up to 20 weeks ]
    Response rate according to Positrone Emission Tomography Response Criteria in Solid Tumors [PERCIST] criteria using FDG PET/CT

  4. Maximum Plasma Concentration [Cmax] of etidronate [ Time Frame: 5 weeks ]
    pharmacokinetics [PK] assessment of MBC-11 metabolite

  5. Maximum Plasma Concentration [Cmax] of ara-U [ Time Frame: 5 weeks ]
    PK assessment of MBC-11 metabolite

  6. Peak time [Tmax] for MBC-11 [ Time Frame: 5 weeks ]
    PK parameters assessment of study drug

  7. Peak time [Tmax] for etidronate [ Time Frame: 5 weeks ]
    PK assessment of MBC-11metabolite

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed malignant tumor (breast cancer, prostate cancer etc)
  • Bone metastases, documented by radiographs, bone scan
  • No available standard chemotherapy or no indication for chemotherapy at the time of screening
  • Eastern Cooperative Oncology Group [ECOG] status 0-2
  • Adequate bone marrow function (hemoglobin ≥ 9 g/dL with or without transfusion requirement, absolute neutrophil count ≥ 1500/mm3, and platelets ≥ 75,000/mm3)
  • Adequate liver function (bilirubin ≤ 2 x Upper Limit of Normal [ULN], Alanine aminotransferase [ALT] ≤ 2.5 x ULN).
  • Adequate renal function (creatinine ≤ 1.5 x ULN) and creatinine clearance ≥ 50 mL/min [measured or calculated by nomogram]).

Exclusion Criteria:

  • Systemic chemotherapy and/or investigational therapy within the previous 4 weeks
  • Fracture ≤ 6 month prior the inclusion in the study
  • Brain metastasis
  • Serum calcium levels < 8.5 mg/dL (< 2.2 mmol/L)
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Osteros Biomedica Ltd Identifier: NCT02673060    
Other Study ID Numbers: OB-MBC-01
First Posted: February 3, 2016    Key Record Dates
Last Update Posted: March 29, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes